Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Recruiting · NCT04879043 · Registry updated 2026-09-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-09-17 | NCT04879043 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Heidelberg Pharma AG | 2 |
24 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.